JOSÉ JAVIER FERNÁNDEZ RUIZ-rekin lankidetzan egindako argitalpenak (10)

2016

  1. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

    Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400

2007

  1. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions

    Life Sciences, Vol. 80, Núm. 10, pp. 979-988

2006

  1. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders

    European Neuropsychopharmacology, Vol. 16, Núm. 1, pp. 7-18

2005

  1. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels

    Biochemical Pharmacology, Vol. 70, Núm. 3, pp. 446-452

2003

  1. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors

    European Journal of Medicinal Chemistry

  2. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase

    Journal of Medicinal Chemistry, Vol. 46, Núm. 8, pp. 1512-1522

2002

  1. Endocannabinoid transporter inhibitors

    Current Medicinal Chemistry - Central Nervous System Agents, Vol. 2, Núm. 2, pp. 129-141

  2. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide

    European Journal of Pharmacology, Vol. 449, Núm. 1-2, pp. 99-103

2001

  1. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors

    Journal of Medicinal Chemistry, Vol. 44, Núm. 26, pp. 4505-4508

  2. Nuevas tendencias en la utilidad terapeútica de los cannabinoides

    Anales de Química de la RSEQ, Núm. 2, pp. 14-21